Mr. Hui has a long track record of founding and operating innovative life science companies focused on bringing new treatments to patients. He launched ChemPartner in China in 2002, growing the company into a leading global contract research organization, taking it public in 2010 (under the name ShangPharma Innovation), and selling it for over $350 million in 2017.
Also in 2017, Mr. Hui established ShangPharma Innovation in the United States to facilitate early-stage research aimed at advancing novel treatments and technologies for patients. In addition, he founded Yingli Pharma in 2011 and, with Yingli Pharma, co-founded 280 Bio in 2023. He holds a BS in chemistry from Oregon State University, an MS in chemistry from Tulane University, and an MBA from the NYU Stern School of Business.